J.P. Morgan Reiterates Overweight on Pfizer

J.P. Morgan is out with its report today on Pfizer PFE, reiterating Overweight. In its report, J.P. Morgan writes, "Within our pharma coverage universe, Pfizer clearly stands out, offering an attractive mix of 1) inexpensive valuation (8.0x '11E and 7.8x '12E EPS), 2) multiple near-term catalysts, 3) a high FCF/dividend yield, and 4) limited earnings risk, in our view." J.P. Morgan maintains a $25 PT on PFE. At the time of posting, shares of PFE were trading pre-market at $17.90, up 0.22% from Friday's close.